Ankyra Therapeutics Appoints Robert V. Tighe, an accomplished industry veteran, as Chief Scientific Officer
CAMBRIDGE, Mass., August 07, 2023--Ankyra Therapeutics, a pre-clinical biotechnology company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Robert V. Tighe, as chief scientific officer. He joined the team on July 10, 2023 and brings considerable immuno-oncology drug development experience to the company.
Source: yahoo.com